Certara Products - Simcyp Archives | 第 3 页，共 21 页

Case Study

PBPK Modeling in Adults Enables DDI Risk Assessment in Children with SMA

In 2020, the US FDA approved Risdiplam (Evrysdi®) as the first orally administered drug to…

Becca Bucci2022 年 6 月 2 日

Case Study

PBPK Model Informs Antibody-Drug Conjugate Label for DDIs Without Clinical Trials

Genentech was developing polatuzumab vedotin (Polivy), an anti-CD79b-vc-monomethyl auristatin E (MMAE) antibody-drug conjugate (ADC) to…

Jim Gallagher2022 年 4 月 11 日

Video

Certara Simcyp Simulator 演示

The Simcyp PBPK Simulator is the industry leader and most widely adopted platform for PBPK…

Jim Gallagher2022 年 1 月 20 日

Blog

模型引导的药物开发 (MIDD) 要点—自上而下与自下而上的方法对比

How can the latest modeling and simulation technologies accelerate drug discovery and development? We frequently…

Jim Gallagher2021 年 9 月 2 日

Case Study

使用 Simcyp Simulator 确定 Guanfacine 在儿童中的药物相互作用风险

Guanfacine (Intuniv® XR) extended release (GXR) is an orally administered, selective alpha2A-adrenergic receptor agonist, non-stimulant…

Jim Gallagher2021 年 8 月 26 日

Case Study

Using a PBPK-PD Receptor Occupancy Model to Determine the Optimal Dose of Radiprodil for Neonates

Radiprodil is a selective allosteric modulator of the NR2B N-methyl-D-aspartate receptor GluN2B-NMDA that was being…

Jim Gallagher2021 年 8 月 26 日

Case Study

Bridging Formulations of Quetiapine for Children with Schizophrenia or Bipolar Disorder

Quetiapine is an atypical antipsychotic for treating schizophrenia, bipolar depression, bipolar mania that helps to…

Jim Gallagher2021 年 8 月 26 日

Case Study

Simcyp’s Age-Defining Feature Facilitates Everolimus Dosing in Neonates

Everolimus (Afinitor®) was recently approved as adjunctive therapy for tuberous sclerosis complex (TSC)-associated partial seizures…

Jim Gallagher2021 年 8 月 26 日

Case Study

Eliglustat for Gaucher Disease: Quantifying the Impact of Pharmacogenetic Status on DDIs

In 2014, Eliglustat (Cerdelga®) was approved by the FDA as the first long-term treatment for…

Jim Gallagher2021 年 8 月 26 日

Case Study

Using PBPK for Label Recommendations in Rare Disease: Deflazacort for Duchenne Muscular Dystrophy

Jim Gallagher2021 年 8 月 20 日

Certara Products – Simcyp

PBPK Modeling in Adults Enables DDI Risk Assessment in Children with SMA

PBPK Model Informs Antibody-Drug Conjugate Label for DDIs Without Clinical Trials

Certara Simcyp Simulator 演示

模型引导的药物开发 (MIDD) 要点—自上而下与自下而上的方法对比

使用 Simcyp Simulator 确定 Guanfacine 在儿童中的药物相互作用风险

Using a PBPK-PD Receptor Occupancy Model to Determine the Optimal Dose of Radiprodil for Neonates

Bridging Formulations of Quetiapine for Children with Schizophrenia or Bipolar Disorder

Simcyp’s Age-Defining Feature Facilitates Everolimus Dosing in Neonates

Eliglustat for Gaucher Disease: Quantifying the Impact of Pharmacogenetic Status on DDIs

Using PBPK for Label Recommendations in Rare Disease: Deflazacort for Duchenne Muscular Dystrophy

订阅时事通讯

快捷链接

解决方案

联系我们